Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 1/2024

Inhalt (20 Artikel)

Open Access Research

CD204-positive M2-like tumor-associated macrophages increase migration of gastric cancer cells by upregulating miR-210 to reduce NTN4 expression

Chin-Wang Chen, Hao-Chen Wang, I-Min Tsai, I-Shu Chen, Chang-Jung Chen, Ya-Chin Hou, Yan-Shen Shan

Open Access Research

Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression

Tommaso Montecchi, Giulia Nannini, Domiziana De Tommaso, Chiara Cassioli, Federica Coppola, Maria Novella Ringressi, Fabio Carraro, Antonella Naldini, Antonio Taddei, Giuseppe Marotta, Amedeo Amedei, Cosima T. Baldari, Cristina Ulivieri

Research

PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma

Nai-Wen Su, Shuen-Han Dai, Kate Hsu, Kuo-Ming Chang, Chun-Chuan Ko, Chen-Wei Kao, Yi-Fang Chang, Caleb G. Chen

Open Access Research

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Kinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, Toshiyuki Minami, Yuhei Kinehara, Akihiro Tamiya, Yasuhiko Suga, Tomoki Kuge, Masahide Mori, Hidekazu Suzuki, Satoshi Tobita, Kiyonobu Ueno, Yoshinobu Namba, Satoshi Tetsumoto, Toshie Niki, Osamu Morimura, Akio Osa, Kazumi Nishino, Izumi Nagatomo, Yoshito Takeda, Takashi Kijima, Atsushi Kumanogoh

Open Access Brief Report

Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors

M Costa-Garcia, JJ Rojas, MD Ramos, P Barlabé, P Calvo, J Navas, R Alemany, R Moreno

Open Access Research

Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases

Celine Man Ying Li, Yoko Tomita, Bimala Dhakal, Teresa Tin, Runhao Li, Josephine A. Wright, Laura Vrbanac, Susan L. Woods, Paul Drew, Timothy Price, Eric Smith, Guy J. Maddern, Kevin Fenix

Open Access Research

HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy

Yuqing Wen, Shuyu Ye, Zhengshuo Li, Xiaoyue Zhang, Can Liu, Yangge Wu, Run Zheng, Chenxiao Xu, Junrui Tian, Lanjun Shu, Qun Yan, Feiyan Ai, Jian Ma

Open Access Brief Report

Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype

Russell Towers, Lidia Trombello, Maximilian Fusenig, Antje Tunger, Anna-Lena Baumann, Roberto Savoldelli, Rebekka Wehner, Frederick Fasslrinner, Claudia Arndt, Francesco Dazzi, Malte Von Bonin, Anja Feldmann, Michael P. Bachmann, Manja Wobus, Marc Schmitz, Martin Bornhäuser

Open Access Research

Vaccination against neoantigens induced in cross-priming cDC1 in vivo

Emily S. Clark, Ana Paula Benaduce, Wasif N. Khan, Olivier Martinez, Eli Gilboa

Open Access Research

Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53

Brendan L. C. Kinney, Sreenivasulu Gunti, Vikash Kansal, Connor J. Parrish, Nabil F. Saba, Yong Teng, Mary Katherine Henry, Fang-Yi Su, Gabriel A. Kwong, Nicole C. Schmitt

Open Access Research

Development of a cellular model to study CCR8 signaling in tumor-infiltrating regulatory T cells

Libao Liu, Laurie Rangan, Nathan Vanalken, Qianqian Kong, Susan Schlenner, Steven De Jonghe, Dominique Schols, Tom Van Loy

Open Access Research

Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment

Shu Su, Fungjun Chen, Xin Lv, Liang Qi, Zhou Ding, Wei Ren, Ming Wei, Ye Liu, Lixia Yu, Baorui Liu, Lifeng Wang

Open Access Research

Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies

Xinfeng Chen, Binghe Tan, Haizhou Xing, Xuan Zhao, Yu Ping, Zhen Zhang, Jianmin Huang, Xiujuan Shi, Na Zhang, Boxu Lin, Weijie Cao, Xin Li, Xudong Zhang, Ling Li, Zhongxing Jiang, Mingzhi Zhang, Wei Li, Mingyao Liu, Bing Du, Yi Zhang

Open Access Research

A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients

Ya-Xian Wu, Bo-Yu Tian, Xin-Yuan Ou, Meng Wu, Qi Huang, Run-Kun Han, Xia He, Shu-Lin Chen

Open Access Research

Protective effect of low‐intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4+ T-cell differentiation

Shuai Fu, Zihong Guo, Xiangli Xu, Yifei Li, Stephen Choi, Peng Zhao, Wenqian Shen, Fei Gao, Chao Wang, Shuang Chen, You Li, Jiawei Tian, Ping Sun

Open Access Research

Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice

Akashdip Singh, Eline T. A. M. Mommers-Elshof, Saskia V. Vijver, J. H. Marco Jansen, Susanne Gonder, Robert Jan Lebbink, Dominique Bihan, Richard W. Farndale, Louis Boon, Solomon Langermann, Jeanette H. W. Leusen, Dallas Flies, Linde Meyaard, M. Ines Pascoal Ramos

Open Access Research

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

Joanna Baginska, Allison Nau, Ilana Gomez Diaz, Anita Giobbie-Hurder, Jason Weirather, Juliana Vergara, Charlotte Abrecht, Margaret Hallisey, Jenna Dennis, Mariano Severgnini, Julia Huezo, Isabella Marciello, Osama Rahma, Michael Manos, Andrew S. Brohl, Philippe L. Bedard, Daniel J. Renouf, Elad Sharon, Howard Streicher, Patrick A. Ott, Elizabeth I. Buchbinder, F. Stephen Hodi

Open Access Research

Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma

Feihua Chen, Mouchun Gong, Dengcheng Weng, Zhaoqing Jin, Guofeng Han, Ziqiang Yang, Junjun Han, Jianjiang Wang

Open Access Research

Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3

Thomas Eichholz, Florian Heubach, Anne-Marie Arendt, Christian Seitz, Ines B. Brecht, Martin Ebinger, Tim Flaadt, Daniela Süsskind, Lisa Richter, Isabel Hülsenbeck, Leonie Zerweck, Sophia Göricke, Frank Paulsen, Frank Dombrowski, Christian Flotho, Stefan Schönberger, Petra Ketteler, Johannes Schulte, Peter Lang

Open Access Research

Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis

K. E. Blethen, C. P. Wolford, G. L. Pecar, T. A. Arsiwala, E. Adjeroh, L. P. Dykstra, B. N. Kielkowski, P. R. Lockman

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.